News

Tibotec, a division of Janssen-Ortho, has announced that Health Canada has approved Prezista for use in treatment-naive adults, dosed once daily in combination with other antiretroviral agents. The

Interest revenues amounted to $37,047 in the first quarter of 2009, compared with $259,434 in the first quarter of 2008. The change in interest revenue resulted from the

Mr Leach also resigned as a director of Integrated BioPharma, and his director and officer positions with its subsidiaries. Mr Leach will continue to be employed by the

Intercell, a biotechnology company, has initiated a Phase I clinical trial with the company’s vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae. This Phase

Mithridion, a biopharmaceutical company, has announced encouraging results from a Phase I pharmacokinetic and clinical study of MCD-386, its lead drug candidate for Alzheimer’s disease. The Phase I

Elan, a neuroscience-based biotechnology company, and Wyeth have announced that the companies will discontinue the highest of three dosing regimens, 2mg/kg, in the two ongoing Phase III studies

The company has said that the new product is suitable for: students who are about to graduate; people who are between jobs; part-time, temporary or seasonal employees, recent

Encision said that its agreement with Intuitive Surgical will allow Encision access beyond conventional laparoscopy to the next generation of minimally invasive surgery. Jack Serino, president and CEO

The company said that it will establish a new research model designed to advance the strong scientific capabilities of both Pfizer and Wyeth and to support the new